Australia's Emyria soars as it gets ethics approval for EMD-RXS Phase 3 trial
16/08/2022 04:20
** Shares of Emyria Ltd EMD.AX jump as much as 18.4% to
A$0.290, its highest since May 30
** Clinical stage biotech co receives Human Research Ethics
Committee's approval to begin Phase 3 trial for its CBD capsule,
EMD-RX5Emyria urn:newsml:reuters.com:*:nASM000NF4
** Says Phase 3 trial will assess the safety and efficacy of
two-dose strengths of the capsule to improve the symptoms of
psychological distress in patients with a background of chronic
pain
** Stock has fallen 36.4% this year, as of last close
(Reporting by Echha Jain in Bengaluru)
((Echha.jain@thomsonreuters.com))